Literature DB >> 11999593

Intraoperative fetal oxygen saturation during Caesarean section: general anaesthesia using sevoflurane with either 100% oxygen or 50% nitrous oxide in oxygen.

R Parpaglioni1, G Capogna, D Celleno, P Fusco.   

Abstract

BACKGROUND AND
OBJECTIVE: The study was designed to evaluate whether the administration of sevoflurane in 100% oxygen for anaesthesia during Caesarean section would improve fetal and neonatal oxygenation compared with the administration of sevoflurane with 50% nitrous oxide in oxygen.
METHODS: The randomized, single-blind controlled study examined 24 mothers, ASA I-II, at term undergoing Caesarean section who were allocated to receive sevoflurane in either 100% oxygen (n = 13) or 50% nitrous oxide in oxygen (n= 11). General anaesthesia was induced in both groups with thiopental 4-5 mg kg(-1) followed by succinylcholine 1.5 mg kg(-1) to facilitate tracheal intubation. Parturients received sevoflurane given either in 100% O2 or in a 50:50 nitrous oxide and oxygen mixture, using 0.5-1.0% progressive incremental dosing up to 1.5-2.0 MAC. Non-invasive fetal oxygen saturation was measured between induction to delivery, and umbilical artery and vein PaO2 were evaluated at birth.
RESULTS: Intraoperative fetal oxygen saturation increased in all patients after maternal 100% oxygen administration (P < 0.01). Maternal hyperoxygenation significantly increased the umbilical vein and umbilical artery PaO2 and the umbilical artery SaO2 at birth (P < 0.0001).
CONCLUSIONS: Maternal hyperoxygenation significantly improves fetal as well as neonatal oxygenation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999593     DOI: 10.1017/s0265021502000200

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  1 in total

1.  New Aspects in the Diagnosis and Therapy of Fetal Hypoplastic Left Heart Syndrome.

Authors:  Oliver Graupner; Christian Enzensberger; Roland Axt-Fliedner
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-08-12       Impact factor: 2.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.